taprenepag
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00572455)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
MMEL1 agonist
- Prostanoid EP2 receptorAGONIST
Prostanoid EP2 receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1- Mol. weight
- 520.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2107783 ↗
- ChEMBLCHEMBL2105692 ↗
Also known as
- pf04217329
- pf 04217329
- pf-04217329
- pf-04217329
- pf-04217329
- pf-04217329
- pf-4217329
- pf-4217329
- taprenepag
- taprenepag isopropyl
- taprenepag isopropyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00934089 | Phase 2 | Jan 1, 2010 | Pfizer |
| NCT00572455 | Phase 2 | Dec 1, 2007 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2007 |
1 organizations
Page 1 / 1